Investor Presentaiton slide image

Investor Presentaiton

Blazing a trail to the first FDA approved and reimbursed Multi-Cancer test INVESTOR 20 DAY 23 shield GUARDANT TM CRC Lung Launched Shield LDT ECLIPSE Readout May 2022 4Q' 22 Filed PMA with FDA 1Q' 23 Staging data at DDW Launch Shield IVD-CRC 2Q' 23 2024 Multi-Cancer Drives NCD Medicare Reimbursement Medicare & ADLT Status ACS Guidelines ADLT Pricing Late 2023 / mid-2024 NCIRE-LUNG prospective study Readout 2024 USPSTF Guidelines 2026 State-level payer reimbursement opportunity Drives private payer reimbursement Starting enrollment in Multi-Cancer study 2025 2026 Complete Shield- Lung Enrollment Submit for FDA approval Shield-Lung 133
View entire presentation